Understanding Localized Kidney Cancer
A guide for adults who were told a mass on their kidney is, or is likely to be, cancer that is still in the kidney. Most of these are found by accident. Most have several good options.
Welcome
You probably did not come to the doctor about your kidney. About 60 to 70 of every 100 patients with a kidney mass got the scan for something else: back pain, belly pain, a kidney stone, a pre-op clearance. The report named a mass on the kidney as a side finding.
Most patients react two ways at once. First, the word cancer hits and the rest of the sentence vanishes. Second, the urge to get it out by Friday. Both reactions make sense. A localized kidney cancer rarely needs a decision inside a week. A few weeks to read, get a second opinion, and choose is reasonable in almost every case.
This guide walks through what you have and how it gets staged. You will see all of the treatment options, and several are not surgery. It also covers how to ask for a second opinion. It pairs with the Cancer Basics guide, which covers the words and the workup that apply to any cancer.
How to use this guide. Read it at your own pace. Highlight what fits and skip what does not. Bring the questions in Chapter 13 to your next visit. You do not have to remember any of this. Keep the guide somewhere you can find it again.
"I went in for stomach pain"
Most localized kidney cancers turn up on a scan ordered for something else. Going in for back pain and leaving with the word cancer in your chart is jarring.
How most people get here
The textbook signs of kidney cancer used to be blood in the urine, flank pain, and a lump you could feel. That triad is uncommon in 2026. Most localized kidney cancers are seen first by a radiologist reading a scan that was ordered for something else: back pain, an ER visit for belly pain, pre-op imaging for hip surgery, a workup for a kidney stone. The radiology report mentions a mass on a kidney, and the next phone call sets up dedicated kidney imaging.
About 60 to 70 of every 100 patients with localized kidney cancer feel fine when they are diagnosed. The mass is found on a scan done for some other reason, before it causes any symptom.
What localized means
Localized means the cancer is still inside the kidney. Scans show no sign that it has reached lymph nodes or other organs. Most kidney cancers today are found at this stage. Most people in this group will not die of it.
What "renal cell carcinoma" means
The medical name for the most common kind of kidney cancer is renal cell carcinoma, often shortened to RCC. It starts in the cells that line the tiny filtering tubes inside your kidney. There are several subtypes, all under the RCC umbrella. The most common is clear cell. You will see your subtype on the pathology report once tissue is looked at.
Patients often phrase it as "I went in for stomach pain and now I have cancer." There was no warning sign you missed.
How much time you have to decide
A localized kidney cancer rarely forces a decision inside a week. Most patients have two to six weeks to read, ask questions, and get a second opinion. Your team will tell you if something about your case shortens that window.
How a kidney mass gets worked up
Once a mass shows up on a scan, your team does a focused workup. The goal is to map the mass, check the rest of the body, and look at your kidney function before any treatment is picked.
Dedicated kidney imaging
- CT of the belly with and without IV contrast. The main test. Some teams call it a renal mass protocol CT. The contrast is what shows whether the mass lights up the way a cancer does, or stays dark the way a simple cyst does.
- MRI of the belly. Used when contrast dye is not safe for you, when the CT picture is not clear, or when the team needs a closer look at the kidney's main vein.
Checking the rest of the body
- CT of the chest. Used to check the lungs, which are the most common place kidney cancer can show up if it has spread. A chest X-ray may be enough for a very small low-risk mass.
- Brain or bone scans. Not done as part of routine staging. Only ordered if you have a symptom or a lab that points there.
PET scans are not the standard staging test for kidney cancer.
Solid versus cystic
Your scan may use a system called Bosniak to describe a mass that has fluid inside it. Simpler cysts (Bosniak I and II) are almost always benign and need no follow-up. Mixed or complex cysts (IIF, III, IV) may need follow-up scans, biopsy, or treatment. Your team will explain which category yours falls in.
A solid mass that lights up with contrast is treated as cancer until proven otherwise. That said, about 15 to 20 out of 100 small solid kidney masses turn out to be benign once tissue is looked at. That is one of the reasons biopsy is so useful (see Chapter 3).
The labs
You will get blood work and a urine test. The blood work checks blood counts, kidney function, liver numbers, and calcium. The two kidney numbers are creatinine and the estimated glomerular filtration rate (eGFR). Your baseline kidney number affects the choice between partial and whole-kidney surgery.
eGFR is a single number from a routine blood test that estimates how well your kidneys filter blood. Losing kidney tissue affects a patient with an eGFR of 90 very differently from one with an eGFR of 50. Ask the team for the number and what it means for your case.
Biopsy: a normal step
A needle biopsy of a kidney mass used to be unusual, and it is now offered more often. A biopsy is most useful when the result would change the plan. It is not done for every small mass, and many small masses are treated or watched without one.
What a kidney biopsy is
A radiologist uses a CT or ultrasound to guide a thin needle through the skin into the mass and take a small sample, which goes to pathology. The mass itself is not removed, only a few cells. The procedure is done with numbing medicine and light sedation, and most people go home the same day.
Why your team may suggest it
- To see if the mass is cancer at all. About 15 to 20 out of 100 small solid kidney masses turn out to be benign. A benign biopsy can end the whole conversation.
- To pick between watching and treating. For a small mass, the grade and subtype from a biopsy can help you and your team choose between watching, a needle treatment, or surgery.
- Before ablation. If a heat or freeze treatment is planned, biopsy is often done at the same session. The mass is not coming out, so this is the chance to learn what it is.
- If you have had another cancer before. A kidney mass in someone with a past lung, breast, or other cancer can sometimes be a spread of that older cancer. The kidney spot is not a new cancer in that case, and the treatment for it is very different, so a biopsy is what sorts this out.
What about tumor seeding
An older worry was that the needle could track cancer cells along its path on the way out. Modern biopsy uses an outer sheath that keeps the needle isolated from the surrounding tissue. Large reviews of biopsied patients put the risk of meaningful tumor seeding well below 1 in 10,000.
When biopsy may be skipped
You may not need a biopsy if you are young, healthy, and have a 5 cm mass that looks like cancer on the scan, and you are going to surgery either way. The choice to biopsy or not is shared by you and your urologist.
If surgery is being recommended for a small mass and biopsy has not come up, ask your team: "Would a biopsy first change anything?" Sometimes the answer is yes, and the result could shift you to surveillance or to ablation. Sometimes the answer is no, for a clear reason.
Size, stage, and what they decide
In localized kidney cancer, size is the single most useful number. It affects which treatments are options for you. The full T, N, M staging system is in the Cancer Basics guide.
The size buckets
All of the above assume the cancer is still inside the kidney, with no node or distant spread on scans. That is what "localized" means. Once it crosses out of the kidney into the main vein, into nearby fat outside a thin lining, or into lymph nodes, the conversation changes. The advanced kidney cancer guide picks up that story.
Grade and subtype
The pathology report will give a subtype (clear cell is the most common; papillary and chromophobe are next) and a grade on a 1 to 4 scale. Lower grade looks closer to normal cells. Grade 4 includes more aggressive looking patterns called sarcomatoid or rhabdoid. Subtype and grade do not change whether you are localized. They do affect your surveillance plan afterward, and in higher-risk cases they can make extra treatment after surgery an option (see Chapter 9).
Why your team uses extra scoring systems
Beyond the T size bucket, surgeons may use a nephrometry score. This is a number that shows how tucked in the tumor is, how close it sits to the urine drainage path, and how close it sits to the main blood vessels. A higher score means a harder partial kidney surgery. There are also risk scores (with names like UISS, SSIGN, or Leibovich) that pull stage, grade, and other features into one number. They help set your follow-up plan after surgery.
The single most useful fact to carry from one visit to the next is your tumor diameter in centimeters. Write it on the same page as your eGFR. Most of the treatment choices in the next chapter depend on this one number, and it is the first thing a second-opinion urologist will ask you.
Your treatment options, by size
Localized kidney cancer has more treatment choices than most cancers. The right one depends on your tumor size and location, your kidney function, your other health, your age, and what matters to you.
Side-by-side comparison
| Option | Hospital stay | Recovery time | Effect on kidney function | Best fit |
|---|---|---|---|---|
| Active surveillance | None | None (unless or until treated) | None from watching itself | Small masses under 4 cm, especially under 3 cm. Older patients or those with other serious health conditions. Some younger patients with very small masses after a careful talk. |
| Heat or freeze treatment (ablation) | Same day or one night | Days | Minimal | Small masses (usually under 3 cm; up to 4 cm in some cases). Older patients or those at higher surgical risk. People who want to avoid a bigger surgery. |
| Partial kidney surgery | 1 to 3 days | 2 to 6 weeks | Modest. Most of the kidney's work is preserved. | Most T1 tumors (under 7 cm) when the location allows. Anyone with a reason to protect kidney function over the long haul. |
| Whole-kidney surgery | 1 to 3 days | 2 to 6 weeks | About 20 to 30 percent of overall kidney function lost on average | Larger tumors (most T2 and many T1b that are centrally placed). When partial surgery is not safely feasible. A healthy patient with a normal other kidney. |
About the small renal mass and surveillance
Active surveillance is one of the standard options for a small kidney mass, on a par with the others in the table. Small masses (under 4 cm, and even more so under 3 cm) grow about 2 to 3 mm per year on average. Roughly 1 in 5 turn out to be benign on biopsy. For patients who fit the criteria, the chance a small mass spreads while being watched is about 1 to 2 in 100 over 5 to 7 years. Around 20 to 30 of every 100 patients on surveillance switch to treatment within 5 years. Almost all are still curable at that point.
Chapter 7 covers what surveillance actually involves.
What is not standard
A few things you may hear about that are not standard treatment for localized kidney cancer:
- Standard radiation is not used as a first treatment. Kidney cancer does not respond well to it.
- Chemotherapy does very little for clear cell kidney cancer. It is not used for localized disease.
- Hormone therapy is not used.
There is a focused, high-dose form of radiation called stereotactic body radiation, or SBRT. It is being studied for some people who cannot have surgery. It is not yet a standard.
About heat or freeze treatment
Ablation uses a thin probe placed into the tumor to destroy it in place with heat or cold. It can be a fit for select small masses, especially in older or higher-risk patients. The main methods:
- Cryoablation. A probe uses very cold gas to freeze the tumor.
- Radiofrequency ablation. A probe heats the tumor, and the heat comes from radio waves.
- Microwave ablation. A newer heat method. More centers use it each year.
- Electrical pulse method (called irreversible electroporation). Used when heat or cold could harm the urine drainage path or the bowel.
How ablation is done
An interventional radiologist places the probe through your skin while you are sedated. They use CT or ultrasound to guide it. Most people go home the same day or the next morning. In some cases a urologist places the probe through a small belly cut instead. That choice is common if the tumor sits near the bowel or other organs.
What the data shows
- For tumors under 3 cm, 5-year cancer results look close to surgery in many studies.
- The tumor comes back in the same spot more often than after partial surgery. The range is about 5 to 15 out of 100, based on the tumor and the method.
- The tumor can come back. A second ablation or a later surgery can often handle it.
- Ablation almost always comes with a biopsy. Nothing is taken out, so the biopsy is the only way to know what was treated.
Where ablation is less of a fit
Ablation is less of a fit for tumors larger than about 3 to 4 cm, and for tumors in tricky spots close to other organs. It is also less of a fit for young, very healthy patients, where partial kidney surgery has the lowest chance of the tumor coming back over many years. Some insurance plans want proof that surgery is too risky for you before they will pay for ablation. Your team will know your plan's rules.
Ask which method the team uses, how many cases they do per year, and what your chance is of needing a second ablation or a later surgery. Results for ablation track closely with how many cases the team does.
Partial or whole kidney: the surgical choice
If surgery is your path, the main question is how much kidney comes out. That choice affects your kidney function for the rest of your life.
Partial kidney surgery (partial nephrectomy)
The surgeon removes the tumor along with a small rim of normal tissue and sews the cut surface closed. The rest of the kidney stays. For most T1 tumors (under 7 cm), partial kidney surgery gives the same cancer control as removing the whole kidney, and it preserves a lot of kidney function. Many surgeons consider it the preferred option for these tumors when the anatomy allows.
The main short-term risks are bleeding and a urine leak from the cut surface. About 3 to 5 in 100 partial nephrectomies need a blood transfusion. About 2 to 4 in 100 have a temporary urine leak, which usually settles with a small drain or a ureteral stent. Less often, a weak spot can form in a kidney artery at the cut surface, called a pseudoaneurysm. It can cause blood in the urine a few weeks after you go home, and it is fixed by threading a thin tube into the artery to seal it, not with another open operation. Call your team if you see new blood in your urine a few days or weeks after surgery.
Whole-kidney surgery (radical nephrectomy)
The surgeon takes out the whole kidney along with the fat around it. This is the right operation when the tumor is too big or too central, or too close to the main vessels for a partial to be safe. It is also a fair choice for some healthy people with a normal other kidney, where the long-term cost to kidney function is smaller.
Why this matters beyond the cancer
Two healthy kidneys give your body a buffer. When you lose part of one, or all of one, the other has to do more. For a young, healthy person with a normal other kidney, life with one kidney is usually fine. For someone with diabetes, high blood pressure, or a kidney number that is already low, losing a whole kidney can lead to long-term kidney disease. A partial can prevent that. Lower kidney function over the years is also tied to higher heart risk.
How surgery is done in 2026
- Robotic. The most common way for both partial and whole-kidney surgery at busy centers. Small cuts, less pain, faster recovery.
- Laparoscopic. Also uses small cuts. Less common for partial now that the robot is widely used.
- Open. A larger cut. Used for very tricky or very large tumors, or at centers without robotic expertise. Cancer results are the same with skilled open surgeons.
Questions to ask your surgeon
- Is partial kidney surgery feasible for my tumor? If not, why not?
- How many partial kidney surgeries do you and your center do per year?
- What is the chance you would need to switch to whole-kidney surgery during my operation?
- What is the chance the pathology shows cancer at the edge of what was removed, and what would the plan be?
Ask your surgeon why partial is not the plan. Sometimes the answer is clear and correct, because the tumor sits centrally and a partial would leave too little kidney behind. Other times, a second opinion at a high-volume center leads to a different answer.
What kidney surgery does not affect
Patients sometimes worry that kidney surgery causes the same kinds of problems as prostate surgery. It does not. Erections and urinary continence are not at risk. Some patients notice a strong urge to pee in the first few weeks while the bladder settles, and that resolves on its own.
Active surveillance for small masses
For a small kidney mass, watching it on a schedule is one of the standard treatment choices. It has structure, regular scans, and a clear trigger to act if the mass changes. It is not the same as doing nothing.
Why it exists for kidney cancer
Small kidney masses (under 4 cm, and even more so under 3 cm) tend to grow slowly. The average is about 2 to 3 mm per year. About 1 in 5 turn out to be benign once biopsied. For people who are older, have other serious health issues, or whose kidney function is already low, the risk from treatment can be greater than the risk from the mass. Long-term results from large surveillance registries are very good, with very few deaths from the cancer.
Who is a fit
- A mass under 4 cm, and even more so under 3 cm.
- Older age, or other health issues that raise the risk of surgery.
- A kidney number that is already below normal. In that case, surgery could push you toward dialysis.
- A patient who, after a full talk, wants to watch first.
- Some young, healthy patients with very small (under 2 cm) low-risk masses, after a shared talk about the trade-offs.
What surveillance looks like
- A biopsy at the start in many cases. A benign biopsy can end the watching entirely.
- Scans every 3 to 6 months for the first 1 to 2 years.
- Scans every 6 to 12 months after that if the mass is stable.
- Yearly scans longer term.
- Chest imaging on a periodic schedule.
- Kidney and other labs on a periodic schedule.
What triggers a switch to treatment
- The mass grows faster than about 5 mm per year.
- The mass reaches around 4 cm.
- The look of the mass on scans changes in a worrying way.
- New symptoms tied to the mass.
- You decide you no longer want to watch. That alone is a valid reason.
What surveillance asks of you
Surveillance works only if you keep the scan appointments on the calendar. The safety of the plan rests on catching a change early and treating it then.
About 20 to 30 of every 100 patients on surveillance for a small mass do switch to treatment within 5 years. Almost all are still curable at that point.
Living after treatment, and the other kidney
After treatment, the goal is to keep your other kidney healthy for the rest of your life. Most of the work is everyday habits.
The first few weeks after surgery
Most people are walking the day of surgery and home in 1 to 3 days. Robotic and laparoscopic incisions hurt less than the older open approach. You can usually get back to desk work in 2 to 4 weeks. Heavier lifting and sport in 4 to 6 weeks. Your team will give you specific instructions on what to avoid in the first month.
Your kidney number after surgery
Your eGFR (kidney number) often dips a bit after surgery. Then it comes back up over weeks to months. After partial kidney surgery, most of it tends to come back. After whole-kidney surgery, the other kidney takes on more work. Your overall function settles around 20 to 30 percent below where you started on average, though this depends on your baseline kidney health. Patients who start with two well-functioning kidneys lose less than those whose function is already reduced.
Protecting the OTHER kidney
- Blood pressure. Get it checked regularly. Treat it. High blood pressure is the most common reason kidneys fail over time.
- Diabetes if you have it. Tight control over the long haul saves kidney tissue.
- Hydration. Steady, not extreme. Aim for pale urine most of the day.
- Stop smoking. Smoking is a risk factor for kidney cancer in the first place and worsens healing.
- Be careful with anti-inflammatory pills. Pills like ibuprofen and naproxen, taken every day for months, can hurt kidney function. Occasional short use is usually fine. Ask your team.
- Get a yearly checkup that includes a kidney number and a urine test. Catching a change early lets your team act.
The emotional load
Many patients have a delayed "what just happened to me" reaction in the weeks after surgery. It often hits once the rush of decisions has ended and the calendar quiets down. Scanxiety, the dread that builds the week before each follow-up scan, is common. Scheduling scans early in the week gets you results faster. Ask the team whether they reach you by portal or by phone call. Plan an easy evening for results day.
Tell them you had kidney surgery. Some procedures and many medications get dosed by kidney function, and contrast scans need clearance. Anyone prescribing a drug or ordering imaging should know you have one less kidney (or part of one less) before they start.
After surgery: do you need more treatment?
For most people with localized kidney cancer, surgery is the treatment. Nothing else is given after. For a smaller group with higher-risk pathology, a year of immune therapy after surgery is now an option.
When no further treatment is needed
For most localized kidney cancers, and even more so for smaller ones with lower grade, the operation is the only treatment needed. The pathology report comes back and your team goes over it with you. The next step is the follow-up schedule (see Chapter 10).
Adjuvant immune therapy (pembrolizumab)
If your cancer is a higher-risk type of localized clear cell kidney cancer, you may be offered a drug called pembrolizumab (brand name Keytruda) for a year after surgery. The FDA approved this use based on a trial called KEYNOTE-564. It is an immune therapy that works by taking the brakes off your immune system, so it can find any leftover cancer cells.
Who is eligible
The exact eligibility comes from a large trial. In general terms, it can be considered if your pathology shows one of the following:
- A T2 tumor with grade 4 or sarcomatoid features.
- A T3 tumor (the cancer reached fat or the kidney's main vein, but no nodes or distant spread).
- Lymph node involvement that was fully removed at surgery.
- A single spot of spread that was fully removed.
If any of these apply, your team will refer you to a medical oncologist. The conversation with them weighs your risk of recurrence against the side effects of a year on the drug.
What the trade-offs look like
- A year of IV infusions every 3 to 6 weeks.
- Immune side effects can affect almost any organ system: thyroid, lungs, liver, gut, skin, joints, pituitary, others. Most are manageable. Some are serious and need steroids or stopping the drug.
- Most people who are eligible benefit. Some do not. The decision is shared with your medical oncologist.
Other systemic therapies after surgery
Older trials tested targeted pills (the tyrosine kinase inhibitor, or TKI, class) after surgery. The results were mixed, and most of these drugs have fallen out of favor in this adjuvant role. As of 2026, pembrolizumab is the option that comes up first in the conversation.
If your final pathology shows a larger tumor, grade 4 or sarcomatoid features, or any spread outside the kidney that was caught at surgery, ask whether a medical oncology visit is part of the plan. A single appointment is usually enough to tell you whether adjuvant pembrolizumab is a fit for your case.
Surveillance scans and what they look for
After treatment, your team follows you with scans and labs on a schedule. The schedule depends on your tumor and your treatment. The point is to catch a change while it is still treatable.
What a typical schedule looks like
Schedules vary by guideline and by your case. Here is a typical plan after surgery for localized kidney cancer:
- Lower-risk (small T1, low grade, clean edges): a clinic visit, labs, and a scan at 3 to 6 months. Then yearly for 5 years. After that, your team decides with you.
- Middle-risk (larger T1, T2, mid grade): scans every 6 months for 2 to 3 years. Then yearly out to year 5. Sometimes out to year 10.
- Higher-risk (T2 with high grade, sarcomatoid, positive edge, fit for adjuvant therapy): chest and belly scans every 3 to 6 months for the first 2 to 3 years. Then every 6 to 12 months out to year 5 or beyond.
- After ablation: a contrast scan at 3, 6, and 12 months to confirm the spot is dead. Then yearly.
What the scans are looking for
- A return of cancer at the surgery site or near the treated area.
- A spot in the lungs, which is the most common place kidney cancer can show up later.
- A spot in liver, bone, or other places. These are less common.
- A new mass in the other kidney, which is uncommon but watched for.
The labs along the way
Kidney function (eGFR), urine tests, blood counts, and basic chemistry. Kidney function can decline slowly without causing symptoms. Tracking it lets your team catch that early and refer you to nephrology if needed.
When to call between visits
Call your team the same day or go to urgent care for any of these:
- You see new blood in your urine, or blood that keeps coming back.
- You have new, bad pain in your flank or belly.
- You run a fever over 101°F, and even more so with chills, in the weeks after surgery or ablation.
- Your surgery cut turns red, drains, or opens up.
- You have sudden leg swelling, chest pain, or shortness of breath. These can be signs of a blood clot after surgery.
- You cannot pee, or you have new, bad urinary symptoms.
Bring these up at your next visit. They are not urgent. Mention any new flank or back pain that does not go away, or weight loss with no clear cause. Also mention a cough that lingers, bone pain, or headaches. Tell your team if any part of the plan stops making sense to you.
Genes, family, and when to ask
Most kidney cancer is not inherited, though a small share is. Knowing whether yours is part of an inherited pattern can change your follow-up and matters for your blood relatives.
When to think about genetic counseling
About 5 to 8 out of 100 kidney cancers are linked to an inherited syndrome. Your team may suggest a meeting with a genetic counselor if any of the following apply:
- Younger age. Under 46 is a common cutoff.
- More than one tumor. In one kidney, or in both.
- Family pattern. A close relative had kidney cancer. Or more than one relative in the family has had it.
- Personal or family pattern of related issues. Some non-cancer tumors of the brain or spine. Tumors of the adrenal gland called pheochromocytoma. Uterine fibroids that needed surgery in a young woman. Lung cysts or a collapsed lung with no clear cause. Some skin findings.
- A specific tumor type. Some rare kidney cancer subtypes are linked to inherited syndromes.
Syndromes you may hear about
- Von Hippel-Lindau (VHL). Many clear cell kidney tumors at younger ages. Also tumors in the brain, eye, adrenal glands, and pancreas.
- Birt-Hogg-Dubé. A mix of kidney tumor types, skin bumps on the face, and lung cysts.
- HLRCC (Hereditary Leiomyomatosis and Renal Cell Cancer). A fast-growing papillary kidney cancer, plus skin bumps. In young women, it can also cause uterine fibroids.
- Hereditary Papillary RCC. This causes many papillary kidney tumors. They can grow in one or both kidneys.
- Others. A few rarer patterns are linked to kidney cancer too. These include SDH-related cancers, tuberous sclerosis, and BAP1 syndrome.
What testing changes
- Surgical plan. In some syndromes, the plan is to wait on surgery until a tumor reaches about 3 cm. More tumors are likely over a lifetime, so saving kidney tissue matters.
- Follow-up. More scans, sometimes including MRI of the brain or spine, and lab tests for related issues.
- Family screening. Blood relatives can take the same test to see if they carry the gene change.
- Other-organ screening. Skin, eye, lung, or gyn checkups, based on the syndrome.
About insurance
A federal law called GINA keeps health insurance and employers from using your gene test results against you. It does not cover life, disability, or long-term care insurance. The genetic counselor will go over these points with you before testing.
If genetic testing turns up a syndrome in you, your blood relatives can be tested for the same gene change with a single blood or saliva test. It is a much smaller workup than the one you went through. A positive result in a relative usually changes their screening schedule, not their daily life.
How to read survival numbers
Most people with localized kidney cancer do well. Numbers you look up online are an average. Your number depends on the size and grade of your tumor and on your overall health.
The big picture
Across all localized kidney cancers, 5-year cancer-specific survival is roughly 90 to 95 out of 100. That number pools tumors of every size and grade together. Small low-grade tumors do better than that, and large high-grade tumors do somewhat worse.
These are population averages. They describe groups of patients with the same stage, not a guarantee for any single person. Once your pathology is back, your team can give you a number that fits your tumor and your overall health more closely.
Why numbers in different places do not match
- Different patient groups. A center that sees mostly very small tumors will report higher numbers than one that sees mostly very large tumors.
- What gets counted. "Overall survival" counts every death, from any cause at all. "Cancer-specific survival" counts only the deaths from kidney cancer.
- Older data. Treatments have gotten better. Numbers from 10 to 20 years ago show worse results than what people get today.
- Different time windows. 5-year, 10-year, and 15-year survival are different views.
Where to read more
The Cancer Basics guide walks through survival numbers in more depth. That includes the gap between median and mean survival, and how to read survival curves.
What the team is aiming for
For most patients with localized kidney cancer, the goal is to stay cancer-free for the long term, ideally for good. Most patients hit that target. In the smaller group where the cancer comes back, the follow-up schedule in Chapter 10 is built to catch the change early, when further treatment has the best chance of working.
Two patients with a tumor of the same size and grade can have different courses. Survival data helps set the plan at the start. Once you are on your follow-up schedule, your team is watching your scans, your labs, and your symptoms, and adjusting the plan based on what they see.
Questions to ask your team
Bring this list to your next visit. You do not have to ask all of them. Pick the ones that fit your situation.
About your tumor
What is the size of my tumor in centimeters?
Most of what comes next depends on this number. Write it down.
What T stage is it, and is it confirmed to be inside the kidney only?
Localized means inside the kidney. Confirm there is no node or distant spread on staging.
Has anyone biopsied it, and would a biopsy change anything?
Ask this especially for masses under 4 cm.
About the options
Is active surveillance a fit for me?
Ask even if surgery seems like the plan, and especially for small masses or for older patients.
Is heat or freeze treatment (ablation) on the table?
Ask this for small masses, or if your surgical risk is higher.
If surgery is the plan, can it be a partial?
If a whole-kidney surgery is the plan for a T1 tumor, this question is fair to ask.
About the team
How many partial kidney surgeries does the surgeon do each year?
For this operation, results track with how often the team does it.
Has my case been seen at tumor board?
A fair ask for odd pathology, very large tumors, or a hint of a hereditary cause.
About what comes after
What surveillance schedule are we using?
Get the timing in writing.
What will happen to my kidney function?
Ask for a number range. Ask what change would push you to need a kidney doctor.
Should I see a medical oncologist?
Ask this if your pathology shows higher-risk features after surgery.
Should I see a genetic counselor?
Ask this if you are under 46 or have more than one tumor. Also ask if you have a family pattern or related health issues.
Words to know
A pocket list of words your team and your reports will use. The Cancer Basics guide covers the general cancer words. Here are the ones tied to kidney cancer.
- Renal cell carcinoma (RCC)
- The most common kind of kidney cancer. Starts in the cells that line the small filtering tubes inside the kidney.
- Clear cell, papillary, chromophobe
- The three most common subtypes of RCC, named for how they look under the microscope.
- Sarcomatoid or rhabdoid features
- Aggressive looking patterns under the microscope that put the tumor in the highest grade group.
- Small renal mass
- A kidney mass 4 cm or smaller. The size where surveillance, biopsy, and ablation are most often options.
- Bosniak classification
- A system used to describe how complex a fluid-filled kidney mass looks on imaging, from I (simple cyst) to IV (clearly cancer).
- Renal mass protocol CT
- A CT scan of the belly done with and without contrast dye to study a kidney mass.
- Renal mass biopsy
- A needle biopsy of a kidney mass, usually done through the skin with CT or ultrasound guidance.
- Nuclear grade
- A 1 to 4 score that captures how abnormal the cell nuclei look under the microscope. Lower is closer to normal.
- Partial nephrectomy
- Surgery that removes the tumor plus a small rim of normal tissue, leaving most of the kidney behind. Also called nephron-sparing surgery.
- Radical nephrectomy
- Surgery that removes the entire kidney along with the surrounding fat.
- Warm ischemia time
- The minutes during partial kidney surgery when blood flow to the kidney is briefly clamped. Shorter is better for kidney function.
- Nephrometry score
- A scoring system that captures how complex a tumor is for surgical planning. Higher means a tougher partial surgery.
- Cryoablation, radiofrequency ablation, microwave ablation
- Methods that destroy a tumor in place using cold or heat through a probe placed in the tumor.
- Active surveillance
- A structured plan of imaging and labs that watches a small kidney mass over time, with a clear trigger to switch to treatment if it changes.
- Adjuvant therapy
- Treatment given after surgery to lower the chance of cancer coming back. For kidney cancer, the main adjuvant option is a year of pembrolizumab in higher-risk cases.
- Pembrolizumab (Keytruda)
- An immune therapy drug that can be given for a year after surgery for higher-risk localized clear cell kidney cancer.
- eGFR
- Estimated glomerular filtration rate. The number that summarizes how well your kidneys filter blood.
- Chronic kidney disease (CKD)
- Long-term reduced kidney function, usually defined by certain eGFR cutoffs over time.
- VHL, BHD, HLRCC, HPRC
- Inherited syndromes that raise the chance of kidney cancer. Each has its own pattern of other findings.
- Tumor board
- A regular meeting where urology, medical oncology, pathology, radiology, and sometimes radiation oncology discuss complex cases together.
Sources and further reading
This guide draws on national guidelines, large registries, and major trials. The list below is a starting point if you want to read further or share specific references with your team.
- European Association of Urology. Renal Cell Carcinoma Guidelines, current version.
- National Comprehensive Cancer Network (NCCN). Kidney Cancer Guidelines, including patient-friendly versions on the NCCN website.
- DISSRM Registry. A long-running multicenter registry of patients on active surveillance for small renal masses. Published analyses form the evidence base for surveillance in this guide.
- KEYNOTE-564 Trial. Choueiri TK, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. New England Journal of Medicine, 2021, with later overall survival updates.
- Bosniak Classification Update. Silverman SG, et al. Bosniak Classification of Cystic Renal Masses, Version 2019. Radiology.
- World Health Organization (WHO). Classification of Urinary and Male Genital Tumors, 2022 edition.
- EORTC 30904. Van Poppel H, et al. A prospective randomized trial of nephron-sparing surgery versus radical nephrectomy. European Urology, 2011.
- National Cancer Institute. Kidney Cancer Treatment (Adult). cancer.gov.
- American Cancer Society. Kidney Cancer overview and treatment pages. cancer.org.
- Kidney Cancer Association. kidneycancer.org. Patient resources and second-opinion guidance.
Companion WellPrept guides
- Cancer Basics. A walk through the words and ideas that apply to any cancer. Topics include staging, grade, follow-up, numbers, and trials.
- Advanced Kidney Cancer. For people whose kidney cancer has spread or has come back.
About this guide. Written by the WellPrept Clinical Team. Reviewed by board-certified urologists. Designed to be read alongside your team's instructions, not as a replacement for them.